Oregon is currently home to 1212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Beat Childhood Cancer Specimen Banking and Data Registry
NCT04715178
Recruiting
This is an observational data registry study of pediatric cancer patients at participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Gender:
ALL
Ages:
All
Trial Updated:
06/10/2025
Locations: Randall Children's Hospital, Portland, Oregon
Conditions: Pediatric Cancer, Survivorship
Register for Updates
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
NCT04260256
Recruiting
In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
Register for Updates
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon
Conditions: Brain Metastases
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: Saint Charles Health System, Bend, Oregon
Conditions: Breast Cancer
Register for Updates
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT06524882
Recruiting
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logM... Read More
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/09/2025
Locations: River View Family Eyecare, Albany, Oregon
Conditions: Amblyopia
Register for Updates
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
06/09/2025
Locations: Casey Eye Institute, Portland, Oregon
Conditions: Amblyopia
Register for Updates
Histamine as a Molecular Transducer of Adaptation to Exercise
NCT05206227
Recruiting
This study is investigating the role of histamine in generating adaptation to exercise
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/09/2025
Locations: University of Oregon, Eugene, Oregon
Conditions: Postexercise Hypotension
Register for Updates
Bevacizumab Treatment For Type 1 ROP
NCT04634578
Recruiting
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Gender:
ALL
Ages:
6 months and below
Trial Updated:
06/09/2025
Locations: Casey Eye Institute, Portland, Oregon
Conditions: Retinopathy of Prematurity
Register for Updates
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to \<13 years of age.
Gender:
ALL
Ages:
Between 3 years and 13 years
Trial Updated:
06/09/2025
Locations: River View Family Eyecare, Albany, Oregon
Conditions: Amblyopia
Register for Updates
Safety Evaluation of THC-Free Hemp Protein Isolate
NCT07022275
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are: Does twice-daily consumption of 20 grams of Agoge Hemp Protein Powder for 30 days result in detectable levels of THC-COOH, the primary metabolite of THC, in urine samples? Is the supplement well tolerated, and does it affect common clinical... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/06/2025
Locations: Helfgott Research Institute, Portland, Oregon
Conditions: Tolerability of Hemp Protein
Register for Updates
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Retina Northwest, Portland, Oregon
Conditions: Wet Age-related Macular Degeneration
Register for Updates
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
NCT06023459
Recruiting
This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural settings. We will randomize 144 eligible individuals with moderate to severe OUD in a 2:1 ratio to one of two medication conditions: (1) XR-BUP (128mg target), administered every 4 weeks or (2) SL-BUP (16mg-24 mg/day target).Participants will receive study medication trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Oregon Health & Science University Primary Care Clinic, Scappoose, Scappoose, Oregon
Conditions: Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Register for Updates